

Supporting Information for

Dinuclear gold(I) complexes with pyrimidine- and *m*-carborane-based bisphosphine ligands: synthesis, structure, photoluminescence and cytotoxicity against malignant pleural mesothelioma

Elena E. Bardina,^a Egor M. Matnurov,^b Ivan V. Bakaev,^a Mariana I. Rakhmanova,^a Maria P. Davydova,^a Alexander V. Artem'ev,^{a*} Maria V. Babak,^{b*} Artem L. Gushchina^{a*}

^a Nikolaev Institute of Inorganic Chemistry SB RAS, 3 Acad. Lavrentiev Avenue, Novosibirsk, 630090, Russian Federation

^b Drug Discovery Lab, Department of Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong SAR, 999077, People's Republic of China

Table of contents

Table S1. Crystal data and structure refinement for **Au1** and **Au2·1.8CH₂Cl₂**

Table S2. Selected geometric parameters for crystal structures of **Au1** and **Au2·1.8CH₂Cl₂**

Fig. S1. Molecular packing of **Au1**

Fig. S2. Molecular packing of **Au2·1.8CH₂Cl₂**

Fig. S3. Decay time for **Au1** (left) and **Au2** (right), T = 300 K

Fig. S4. Concentration-effect curves for **Au1**, L1, Au(tht)Cl, and cisplatin in AB1, JU77, and MRC-5 cell lines upon 72 h exposure

Fig. S5. UV-Vis spectra of complexes **Au1** and **Au2** in CH₂Cl₂.

Table S1. Crystal data and structure refinement for **Au1** and **Au2·1.8CH₂Cl₂**

	Au1	Au2·1.8CH₂Cl₂
Chemical formula	C ₂₈ H ₂₂ Au ₂ Cl ₂ N ₂ P ₂	C _{61.8} H _{79.6} Au ₄ B ₂₀ C _{17.6} P ₄
M _r	913.25	2219.96
Crystal system, space group	Triclinic, <i>P</i> 1	Monoclinic, <i>C2/c</i>
<i>a</i> , <i>b</i> , <i>c</i> (Å)	9.2240 (2), 13.7796 (3), 21.7778 (4)	32.1688 (10), 13.7076 (4), 18.0035 (6)
α, β, γ (°)	94.548 (1), 91.601 (1), 90.471 (1)	90, 102.182 (1), 90
<i>V</i> (Å ³)	2758.08 (10)	7760.0 (4)
μ (mm ⁻¹)	10.96	7.87
Crystal size (mm)	0.20 × 0.20 × 0.15	0.20 × 0.20 × 0.08
<i>T</i> _{min} , <i>T</i> _{max}	0.422, 0.746	0.479, 0.746
No. of measured, independent and observed [<i>I</i> > 2σ(<i>I</i>)] reflections	51948, 16837, 14870	48239, 10914, 8991
<i>R</i> _{int}	0.045	0.034
(sin θ/λ) _{max} (Å ⁻¹)	0.715	0.695
Range of <i>h</i> , <i>k</i> , <i>l</i>	<i>h</i> = -13→13, <i>k</i> = -19→19, <i>l</i> = -31→31	<i>h</i> = -41→44, <i>k</i> = -19→19, <i>l</i> = -24→25
<i>R</i> [<i>F</i> ² > 2σ(<i>F</i> ²)], <i>wR</i> (<i>F</i> ²), <i>S</i>	0.030, 0.073, 1.07	0.031, 0.073, 1.03
No. of reflections	16837	10914
No. of parameters	750	563
No. of restraints	739	564
Weighting scheme	<i>w</i> = 1/[σ ² (<i>F</i> _o ²) + 0.8746 <i>P</i>] where <i>P</i> = (<i>F</i> _o ² + 2 <i>F</i> _c ²)/3	<i>w</i> = 1/[σ ² (<i>F</i> _o ²) + (0.0259 <i>P</i>) ² + 44.2983 <i>P</i>] where <i>P</i> = (<i>F</i> _o ² + 2 <i>F</i> _c ²)/3
Δρ _{max} , Δρ _{min} (e Å ⁻³)	1.58, -2.15	3.43, -1.86

Computer programs: *APEX3* (Bruker-AXS, 2016), *SAINT* (Bruker-AXS, 2016), *SHELXT* 2018/2 (Sheldrick, 2018), *SHELXL2019/2* (Sheldrick, 2019), *ShelXle* (Hübschle, 2011), *enCIFer* (Allen *et al.*, 2004).

Table S2. Selected geometric parameters for crystal structures of **Au1** and **Au2·1.8CH₂Cl₂**

Au1			
Distances, Å			
P2—Au2B (1)	2.3068 (10)	Cl3B—Au3B (2)	2.280 (8)
P2—Au2A (1)	2.1629 (9)	Cl3A—Au3A (2)	2.299 (8)
Au1—Cl1 (1)	2.2831 (10)	Au4—Cl4 (2)	2.2835 (9)
Au2B—Cl2B (1)	2.3035 (16)	Au3B—P3B (2)	2.241 (8)
Au2A—Cl2A (1)	2.2987 (16)	Au3A—P3A (2)	2.217 (8)
Au1—P1 (1)	2.2200 (8)	Au4—P4 (2)	2.2260 (9)
Angles, °			
P1—Au1—Cl1	178.38 (4)	P3B—Au3B—Cl3B	175.1 (4)
Cl2B—Au2B—P2	174.16 (5)	P3A—Au3A—Cl3A	172.9 (5)
P2—Au2A—Cl2A	172.57 (5)	P4—Au4—Cl4	176.25 (3)
Au2·1.8CH₂Cl₂			
Distances, Å			
Au1—Cl2	2.2775 (13)	P1—Au2	2.2423 (10)
Au2—Cl4	2.2813 (10)	Au1—P2	2.2357 (11)
Angles, °			
P2—Au1—Cl2	173.99 (5)	P1—Au2—Cl4	177.35 (4)




Fig. S1. Molecular packing of Au1




Fig. S2. Molecular packing of Au2·1.8CH₂Cl₂




Fig. S3. Decay time for **Au1** (left) and **Au2** (right), T = 300 K




Fig. S4. Concentration-effect curves for **Au1**, L1, Au(tht)Cl, and cisplatin in AB1, JU77, and MRC-5 cell lines upon 72 h exposure




Fig. S5. UV-Vis spectra of complexes **Au1** and **Au2** in CH_2Cl_2